Abstract library

80 results for "octreoscan".
#303 Pancreatic Metastases from Bronchopulmonary Atypical Carcinoid: An Uncommon Tumor Spreading to a Rare Location
Introduction: We report an uncommon case of pancreatic metastases from a bronchial atypical carcinoid.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#368 The Role of Image and Chromogranin A Level at Diagnosis: A Portuguese Review of 19 Patients
Introduction: Neuroendocrine tumors (NET) constitute a heterogeneous group of neoplasms. Biochemical neuroendocrine markers offer high sensitivity in establishing the diagnosis and, if correlated with image assessment, can provide important prognostic information.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Pedro Barata
#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients
Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tao Cui
#82 A case of insulinoma successfully treated by means of long-acting somatostatin analogue
Introduction: Insulinoma is the most common hormonally active pancreatic neuroendocrine tumor. Effective treatment represents tumor surgery and medical therapy using diazoxide or streptozotocine. Somatostatin analogue therapy is rarely effective in this type of tumor.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Marek Bolanowski
#540 Diagnositc and Prognostic Role of 68GA-DOTATATE PET in Patients with Neuroendocrine Tumors
Introduction: Octreoscan (OS) is currently the gold standard for diagnosis of somatostatin receptor positive NET but it is limited by a lower spatial resolution and physiological uptake noises. DOTATATE is a somatostatin analogue, radiolabelled with 68Ga and adapted for PET imaging.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR Francesca Marciello
#545 A Case of ACTH-Secreting Bronchial Carcinoid
Introduction: Ectopic ACTH syndrome (EAS) occurs in about 5-10% of ACTH-dependent hypercortisolism and, in up to 15% of cases, is related to occult neoplasms.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1317 Value of Octreoscan and 18FDG-PET for Clinical Prognosis of Patients with Neuroendocrine Neoplasms
Introduction: Despite the existence of biological markers of aggressiveness, the clinical course of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN) remains difficult to predict. Discrepancies between imaging data generated with 111In-pentetreotide scintigraphy (SRS) and 18 F-FDG-PET could reflect the degree of cellular de-differentiation.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Francois Pralong
Authors: Gouffon M, Prior J, Ratib O, Krause T, ...
#90 The prognostic value of FDG-PET scan in neuroendocrine tumors: a retrospective analysis of 46 patients treated in one center
Introduction: Neuroendocrine tumors (NETs) are rare and generally indolent. For diagnostic purposes, the sensitivity of FDG-PET scan is known to be low in this setting, though when positive, its prognostic value is not well-defined in NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Ivan Borbath
#106 Gastroenteropancreatic neuroendocrine tumors: single institution clinicopathological study
Introduction: Neuroendocrine cells are widely distributed throughout the body, and neoplasms from these dispersed cells can arise at many sites. They are distinguished into two broad categories: 1) Tumors identified as small cell lung carcinomas with biology and natural history of a high-grade malignancy and characteristics of small cell undifferentiated or anaplastic appearance by light microscopy. The WHO categorizes these tumors as poorly-differentiated neuroendocrine carcinomas; 2) Well-defined neuroendocrine tumors (NETs) with variable, but most lyindolent biologic behavior and characteristic well-differentiated histologic features. The majority arise in the gastrointestinal tract and collectively they are referred as gastroenteropancreatic neuroendocrine tumors (GEP/NETs). They include carcinoid tumors, pancreatic islet cell tumors (gastrinoma, insulinoma, glucagonoma, VIPoma, somatostatinoma), paragangliomas, pheochromocytomas, and medullary thyroid carcinomas. The WHO classifies the GEP/NETs as well-differentiated NETs (carcinoid tumors) if they are noninvasive and have benign behavior or uncertain malignant potential. In contrast, GEP/NETs with characteristics of low-grade malignancy with invasion of the muscularis propria or beyond, or metastases, are characterized as well-differentiated neuroendocrine carcinomas (malignant carcinoids). Pancreatic islet cell tumors, whether functioning or not, are classified as well-differentiated NETs or well-differentiated neuroendocrine carcinomas, due to the (depending on) histologic characteristics. The WHO classification for gastroenteropancreatic NETs based on stage (ie size and presence of metastases) and grade (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) categorizes them as well-differentiated NETs, e.g., carcinoid tumors, or as well-differentiated neuroendocrine carcinomas.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Michael M. Vaslamatzis
#124 Management and outcomes of malignant paragangliomas and phaeochromocytomas
Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.